SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotechnology Value Fund, L.P.
An SI Board Since January 1998
Posts SubjectMarks Bans
4974 145 0
Emcee:  scaram(o)uche Type:  Moderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromPosted
3399Charles River Laboratories Announces Strong Fourth-Quarter and Full-Year 2002 Rescaram(o)uche2/3/2003
3398FDA Approves Biogen's AMEVIVE(R) (alefacept) for Treatment of Psoriasis Fridscaram(o)uche1/31/2003
3397Gilead Sciences Announces Fourth Quarter and Full Year 2002 Financial Results Thscaram(o)uche1/30/2003
3396Ah, shucks! Not. Bye bye!......... EntreMed Co-Founder John Holaday Steps Dowscaram(o)uche1/29/2003
3395Bush proposal aimed at germ warfare defense Wednesday January 29, 6:17 pm ET Byscaram(o)uche1/29/2003
3394Once again, kudos to Bill and Melinda Gates....... New Gates fund seeks better scaram(o)uche1/26/2003
3393SignalsMag's take on the "H&Q" conference, with emphasis on Ketuck1/25/2003
3392<i>The $60M was in the form of convertible pfd shares exercisable at $3. IBiomaven1/24/2003
3391Yeah, I know about Althexis. At the time, I was hot on the idea of private compscaram(o)uche1/23/2003
3390They raised $60M in conjunction with the reverse merger, microcide and althexis.rkrw1/23/2003
3389>> since I did so well with his former company << Yeah, we shouldn&scaram(o)uche1/23/2003
3388On an Adjusted Basis, Amgen Reports Fourth Quarter Earnings Per Share Increase 1scaram(o)uche1/23/2003
3387Hate to nominate him since I did so well with his former company, Geltex, but...rkrw1/21/2003
3386ATLANTA, Jan. 21 /PRNewswire-FirstCall/ -- AtheroGenics, Inc. (Nasdaq: AGIX - Nenigel bates1/21/2003
3385an interview with, few would disagree, the individual who knows biotech best....scaram(o)uche1/19/2003
3384Genentech Exceeds $2.7 Billion in Revenues with $1.5 Billion in Oncology Sales Wscaram(o)uche1/15/2003
3383FDA Panel Backs Efficacy, Safety of Aldurazyme for MPS I Wednesday January 15, 4scaram(o)uche1/15/2003
3382Biogen, Genentech Fend Off Appeals to Buy Up Rivals By Angela Zimm Cambridge, Mscaram(o)uche1/15/2003
3381Yup. Hadn't noticed their little stake in KOSN; too small to report on the tuck1/14/2003
3380Hi Tuck, This material is usually dated but is this the same BVF? nasdaq.com EVENT HORIZON III1/14/2003
3379Thanks, Tuck. Enjoy that stuff. This is a good post........ Message 18442996scaram(o)uche1/14/2003
3378For those who care, the latest moves by BVF are to reduce NRGN stake somewhat: tuck1/14/2003
3377<<Seems to me small BTs are as a general rule not capable of getting it riMiljenko Zuanic1/13/2003
3376They'll slam tktx tomorrow. It's renal EPs weren't even persuasive keokalani'nui1/13/2003
3375FDA Advisory Committee Provides Positive Review of Fabrazyme(R) ----------------scaram(o)uche1/13/2003
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News